Key result
Chemotherapy linked to ~72% lower mortality in patients with bladder angiosarcoma.
Why the study?
Bladder angiosarcoma is a rare cancer with only sporadic cases reported, and its clinicopathological features and survival outcomes are not well described.
Does chemotherapy improve survival in patients with bladder angiosarcoma?
Population
68 patients with bladder angiosarcoma (35 de novo, 33 radiation-induced)
Comparison
Chemotherapy vs no chemotherapy
Design
Systematic literature review
Follow-up
Median 5 months (interquartile range 3–12)
Authors
Loading...
May support chemotherapy consideration in bladder angiosarcoma; leaves open prospective validation of survival benefit.
Systematic Review (n=68)
Does chemotherapy improve survival in patients with bladder angiosarcoma?
Hazard Ratio: 0.28
p-value: p=0.01
Bladder angiosarcoma is an aggressive disease with poor survival, but chemotherapy is associated with improved prognosis.
Silwal et al. (2025) conducted a systematic review in Bladder angiosarcoma (n=68). Chemotherapy vs. No chemotherapy was evaluated on Survival (HR 0.28, p=0.01). Chemotherapy was identified as an independent prognostic factor associated with improved survival in patients with bladder angiosarcoma (HR 0.28; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: